MedPath

HeiLongJiang ZBD Pharmaceutical Co.,Ltd.

Ownership
-
Established
1996-10-28
Employees
465
Market Cap
-
Website
www.zbdzy.com
Introduction

The company is a large company listed on the Shanghai Stock Exchange dedicated to providing high-quality products and services for human health. As one of the top 100 enterprises in China's pharmaceutical industry, the company focuses on the development direction of innovation and creativity, high quality, and high technology. Its business covers four major sectors: scientific research and development, pharmaceutical industry, traditional Chinese medicine industry, and financial investment. It is one of the most innovative pharmaceutical enterprises in China's pharmaceutical industry. The company's main business is pharmaceutical R&D, production and sales. Main products: 3 protected varieties of traditional Chinese medicine: Cuproton Capsules, Compound Qinlan Oral Liquid, and Pediatric Hot Quick Clear Syrup, as well as 4 exclusive varieties of Compound Qalan Oral Liquid, Lingqi Plus Oral Liquid, and Compound Baitouweng Capsules. The company won the “Leading Power · High-Quality Development of Chinese Medicine” Achievement Enterprise and Achievement Brand Award; it was also shortlisted on the Ministry of Industry and Information Technology's 2022 Green Manufacturing List and on the “National Green Factory List”. The list of China's top 100 pharmaceutical industry series, ranked 26th in the “2022 Chinese Traditional Chinese Medicine Companies”; ranked 21st in the “2022 TOP30 Listed Chinese Medicine Companies”, 22nd in the “2022 Top 100 Chinese Medicine Companies”, 23rd in the “2023 China Proprietary Chinese Medicine Industry TOP100”, 29th in the “2023 China Pharmaceutical R&D Strength Ranking”, and 48th in the “2022 Top 100 Chinese Pharmaceutical Manufacturing Companies”. With high quality development results and representative product - injectable hemostone, it won the title of “Excellent Brand Enterprise of Chinese Ethnic Medicine for the Year 2022 - 2023”.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

73

NMPA:73

Drug Approvals

Bromhexine Hydrochloride Injection

Product Name
盐酸溴己新注射液
Approval Number
国药准字H20244392
Approval Date
Jul 9, 2024
NMPA

Esomeprazole Magnesium Enteric-coated Tablets

Product Name
艾司奥美拉唑镁肠溶片
Approval Number
国药准字H20243685
Approval Date
May 15, 2024
NMPA

Levetiracetam Concentrated Solution for Injection

Product Name
左乙拉西坦注射用浓溶液
Approval Number
国药准字H20243584
Approval Date
Apr 24, 2024
NMPA

Tofacitinib Citrate Tablets

Product Name
枸橼酸托法替布片
Approval Number
国药准字H20243171
Approval Date
Feb 6, 2024
NMPA

Levetiracetam Oral Solution

Product Name
左乙拉西坦口服溶液
Approval Number
国药准字H20234346
Approval Date
Dec 18, 2023
NMPA

Ambroxol Hydrochloride Oral Solution

Product Name
盐酸氨溴索口服溶液
Approval Number
国药准字H20233460
Approval Date
Jul 19, 2023
NMPA

通脉口服液

Approval Number
国药准字Z20174074
Approval Date
Dec 20, 2022
NMPA

Sterile Water for Injection

Product Name
灭菌注射用水
Approval Number
国药准字H23022152
Approval Date
Nov 10, 2021
NMPA

Sterile Water for Injection

Product Name
灭菌注射用水
Approval Number
国药准字H23022154
Approval Date
Nov 10, 2021
NMPA

Sterile Water for Injection

Product Name
灭菌注射用水
Approval Number
国药准字H23022151
Approval Date
Nov 10, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.